Role reversal: Infiltrating T cells protect the brain

Journal of Clinical Investigation

Volumn 125, Issue 2, 2015, Pages 493-494

  Steinman, Lawrence ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 4; HLA ANTIGEN CLASS 2;

BRAIN PROTECTION; ENCEPHALITIS; IMMUNE RESPONSE; IMMUNITY; LYMPHOCYTIC INFILTRATION; NERVE CELL; NERVOUS SYSTEM; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; ANIMAL; BRAIN INJURY; CD4+ T LYMPHOCYTE; DEGENERATIVE DISEASE; IMMUNOLOGY; NERVE FIBER; SIGNAL TRANSDUCTION;

ANIMALS; AXONS; BRAIN INJURIES; CD4-POSITIVE T-LYMPHOCYTES; HISTOCOMPATIBILITY ANTIGENS CLASS II; INTERLEUKIN-4; MAP KINASE SIGNALING SYSTEM; NEURODEGENERATIVE DISEASES;

EID: 84922133550     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI80279     Document Type: Review

References (15)

1. Rivers TM, Sprunt DH, Berry GP. Observations on attempts to produce acute disseminated encephalomyelitis in monkeys. J Exp Med. 1933;58(1):39-53.
2. Steinman L, Zamvil SS. How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann Neurol. 2006;60(1):12-21.
3. Kulcsar KA, et al. Interleukin 10 modulation of pathogenic Th17 cells during fatal alphavirus encephalomyelitis. Proc Natl Acad Sci U S A. 2014;111(45):16053-16058.
4. Garraud K, et al. Differential role of the interleukin-17 axis and neutrophils in resolution of inhalational anthrax. Infect Immun. 2011;80(1):131-142.
5. Steinman L. Nuanced roles of cytokines in three major human brain disorders. J Clin Invest. 2008;118(11):3557-3563.
6. Moalem G, et al. Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. Nat Med. 1999;5(1):49-55.
7. Brocke S, et al. Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein. Nature. 1996;379(6563):343-346.
8. Hauben E, et al. Posttraumatic therapeutic vaccination with modified myelin self-antigen prevents complete paralysis while avoiding autoimmune disease. J Clin Invest. 2001;108(4):591-599.
9. Walsh JT, et al. MHCII-independent CD4+ T cells protect injured CNS neurons via IL-4. 2015;125(2):699-714.
10. Steinman L. The discovery of natalizumab, a potent therapeutic for multiple sclerosis. J Cell Biol. 2012;199(3):413-416.
11. Rudick R, et al. Natalizumab: bench to bedside and beyond. JAMA Neurol. 2013;70(2):172-182.
12. Yednock T, et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against α4β1 integrin. Nature. 1992;356(6364):63-66.
13. Hla T, Brinkmann V. Sphingosine 1-phosphate (S1P): Physiology and the effects of S1P receptor modulation. Neurology. 2011;76(8 suppl 3):S3-S8.
14. Chun J, Brinkmann V. A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya). Discov Med. 2011;12(64):213-228.
15. Novartis. Novartis provides update on fingolimod Phase III trial in primary progressive MS (PPMS). Novartis Web site. http://www.novartis.com/newsroom/media-releases/en/2014/1875463.shtml. Updated December 1, 2014. Accessed December 20, 2014.